Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3050 participants.
Also called NCT04236609
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose other
- Phase
- Not applicable
- Enrolled
- 3,050 participants
- Sponsor
- Registry
-
NCT04236609
-
- Other papers using this trial's data
- Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Austria, Bangladesh, Belgium, Brazil, Czechia, France, Germany, India, Ireland, Italy, Malaysia, Mexico, Netherlands, Poland, Singapore, South Korea, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04236609. Randomized; double masking; primary purpose other. Start 2020-06-15 (actual); primary completion 2023-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global
- Acronym
- ABILITY
- Condition
- Diabetes
- Condition
- Coronary Artery Disease
- Condition
- Acute Coronary Syndrome
- Intervention (Device)
- Abluminus DES+ Sirolimus Eluting Stent System (SES)
- Intervention (Device)
- XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)
- Lead sponsor
- Concept Medical Inc.
Record details
- Record id
cardio:ct-nct04236609- Content hash
ba56b7e8e3dd9987d07f2f8ce0d07ca9f5dcfd8492c0ed6c0eb47d773869680f